why choose us

First received: December 25, 2022

Clinical Trial: Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation

Study Status: Completed

Recruit Status: Completed

Condition: Multiple Myeloma

Study Type: Interventional


Official Title: Efficacy of Response-adapted Treatment Guided by Negative Minimal Residual Disease and Negative Imaging (MRDI) in Fit Patients Diagnosed With Multiple Myeloma Who Are Candidates for Bone Marrow Transp

Brief Summary: To assess whether continued treatment to achieve negative Minimal Residual Disease and Imaging (MRDI(-)) improves therapeutic outcomes in patients with newly diagnosed Multiple Myeloma. The primary endpoints are progression-free survival (PFS) and overall survival (OS). The safety evaluation includes the evaluation of adverse events (which are classified according to the Common Criteria for Terminology for Adverse Events of the National Cancer Institute, version 5.0).

Read more